Pre-Market Analysis on Sarepta Therapeutics, BioMarin Pharma, Theravance, and Chelsea Therapeutics

LONDON, April 8, 2013 /PRNewswire/ --

The U.S. Supreme Court, last year, upheld President Obama's Affordable Care Act (ACA). The ACA is expected to have a significant impact on the biotechnology industry. While the healthcare reform is likely to result in significant increase in costs for the biotechnology industry in the near-term, the increase in the number of insured individuals is likely to benefit the industry in the long-term. For biotechnology companies such as BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Sarepta Therapeutics Inc. (NASDAQ: SRPT), Theravance Inc. (NASDAQ: THRX), and Chelsea Therapeutics International Ltd. (NASDAQ: CHTP), another major trend to emerge in the last year has been increasing competition from generic drugs. On Friday, biotechnology stocks struggled as the broad market came under pressure following disappointing labor market data. StockCall has posted free technical research on SRPT, BMRN, THRX, and CHTP which can be downloaded upon sign up at

http://www.stockcall.com/signup

Shares of BioMarin Pharmaceutical Inc. edged higher in trading on Friday even as the broad market struggled. The stock ended the day 1.35% higher at $61.72 on volume of 990,466. The stock touched an intra-day high of $62. Despite the gains on Friday, BioMarin's shares have fallen more than 2% in the last three trading sessions. The company's shares have had an excellent run so far in 2013. Year-to-date, the stock has gained more than 25%. However, the stock has traded sideways in the last one month. The stock's MACD chart is currently giving bearish signal. Sign up and read the complimentary report on SRPT at

http://www.StockCall.com/SRPT040813.pdf

Shares of Sarepta Therapeutics Inc. rose sharply in trading on Friday despite the decline in the broad market. The stock rose to an intra-day high of $36.94 before finishing the day 5.17% higher at $36.21 on above average volume of 3.56 million. Despite gains registered in its last session, Sarepta's shares have fallen 1.20% in the last three trading days. The biotech company's shares are currently trading well above their 50-day and 200-day moving averages, which is a bullish signal. Year-to-date, the stock has gained more than 40%, outperforming the broad market. The free report on BMRN can be downloaded by signing up now at

http://www.StockCall.com/BMRN040813.pdf

Shares of Theravance Inc. fell in Friday's session. The stock fell to an intra-day low of $22.71 before finishing the day 0.99% lower at $23.06 on volume of 634,020. Theravance's shares have now fallen nearly 5% in the last three trading sessions. The stock has recently slipped below its 200-day moving average, which is a bearish signal. The downbeat trend is further confirmed by the stock's MACD chart. Year-to-date, shares of THRX have gained nearly 3.70%, underperforming the broad market. Free report on THRX can be accessed by registering at

http://www.StockCall.com/THRX040813.pdf

Shares of Chelsea Therapeutics International Ltd. fell sharply in Friday's trading session. The stock closed 1.54% lower at $1.92 after touching an intra-day low of $1.85. Chelsea Therapeutics' shares have now fallen more than 3% in the last three sessions. The company's shares have been struggling to break through $2.10 resistance level. The stock's MACD chart suggests that market sentiment is currently bearish. Register with StockCall and download the research on CHTP for free at

http://www.StockCall.com/CHTP040813.pdf

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at

http://www.stockcall.com  

SOURCE StockCall.com




Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.